



醫院管理局
HOSPITAL
AUTHORITY

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee February 2025 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for unsuccessful application ¹
1	Baricitinib	Olumiant	Skin	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
2	Cabozantinib	Cabometyx	Malignant disease and immunosuppression	Unsuccessful	Insufficient evidence to demonstrate significant clinical outcome benefits
3	Cenobamate	XCOPRI	Central nervous system	Pending	Pending further information
4	Dabrafenib/ Trametinib	Tafinlar/ Mekinist	Malignant disease and immunosuppression	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
5	Dornase alfa	Pulmozyme	Respiratory system	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
6	Elranatamab	Elrexio	Malignant disease and immunosuppression	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
7	Empagliflozin	Jardiance	Endocrine system	Unsuccessful	Alternative(s) available in HADF with comparable benefits
8	Evocalcet	Orkedia	Nutrition and blood	Approved	
9	Ganirelix	Orgalutran	Obstetrics, gynaecology, and urinary-tract disorders	Approved	
10	Lecanemab	Leqembi	Central nervous system	Unsuccessful	Concern regarding safety profile
11	Lorlatinib	Lorviqua	Malignant disease and immunosuppression	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
12	Mepolizumab	Nucala	Ear, nose, and oropharynx	Approved	
13	Mifepristone	Mifegyne	Obstetrics, gynaecology, and urinary-tract disorders	Approved	
14	Nintedanib	Ofev	Respiratory system	Pending	Pending further information
15	Olaparib	Lynparza	Malignant disease and immunosuppression	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
16	Pembrolizumab	Keytruda	Malignant disease and immunosuppression	Approved	
17	Safinamide	Equfina	Central nervous system	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for unsuccessful application ¹
18	Secukinumab	Cosentyx	Musculoskeletal and joint disease	Unsuccessful	Alternative(s) available in HADF with comparable benefits
19	Tezepelumab	Tezspire	Respiratory system	Pending	Pending further information
20	Tofacitinib	Xeljanz	Gastro-intestinal system	Approved	
21	Trastuzumab Deruxtecan	Enhertu	Malignant disease and immunosuppression	Unsuccessful	The justification of the treatment's cost in relation to its benefits is insufficient
22	Tremelimumab/ Durvalumab	Imjudo/ Imfinzi	Malignant disease and immunosuppression	Unsuccessful	Alternative(s) available in HADF with comparable benefits

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.